Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2020-09-16 Report Publication Anno…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (a conference presentation). It provides details such as the date, time, location, and purpose of the event. It does not contain the actual presentation slides or financial report, but rather serves as a notification of the event and the future availability of materials. Therefore, it falls under the category of a regulatory announcement regarding an event.
2020-09-16 Korean
[기재정정]기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KIND system) announcing the scheduling and details of an Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the presentation. Since it is an announcement of an upcoming event rather than the presentation slides themselves, and it follows the standard format for regulatory event notifications, it is classified as a Regulatory Filing (RNS).
2020-08-20 Korean
[기재정정]기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a regulatory filing (a correction report) regarding the postponement of an Investor Relations (IR) event due to COVID-19 social distancing measures. It does not contain the actual presentation materials, but rather serves as a formal notice of a change in schedule for an IR event. Since it is a regulatory announcement regarding corporate events and does not fit into specific categories like 'IP' (which would be the presentation itself) or 'RPA' (which is for report publication), it is best classified as a general regulatory filing.
2020-08-18 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (반기보고서) for the company 'Cellid' (주식회사 셀리드) covering the period from January 1, 2020, to June 30, 2020. It contains detailed financial information, business descriptions, and management disclosures required for a regulatory filing. In the context of Korean financial reporting, a '반기보고서' is a standard interim/quarterly report. Therefore, it is classified as an Interim / Quarterly Report (IR). H1 2020
2020-08-13 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and details of an Investor Relations (IR) event (기업설명회). It provides the date, location, purpose, and agenda for the presentation. Since it is an announcement of an upcoming event rather than the presentation slides themselves, and it is a regulatory notification of an IR activity, it fits best under the 'Regulatory Filings' (RNS) category as it is a standard corporate disclosure of an event schedule.
2020-08-12 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees, including the number of shares, exercise price, and legal basis under the Commercial Act. This type of disclosure regarding capital structure changes and employee compensation via stock options is classified as a 'Share Issue/Capital Change' (SHA) in the provided taxonomy.
2020-08-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.